Data to date suggest SGLT2 inhibitors appear to moderately reduce the risk of the decrease of estimated glomerular filtration rate (eGFR), progression to end-stage renal disease (ESRD), cardiovascular (CV) death, and hospitalization for heart failure beyond simply reducing plasma glucose level [12–17]. This evidence concerns the gene SLC5A2 and heart failure.